Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes

As of June 10th 2020 about 7.2 million individuals have tested positive for, and more than 410,000 have died due to COVID-19. In this review we outline the pathophysiology that underpins the potential use of anti-rheumatic therapies for severe COVID-19 infection and summarize the current evidence re...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Rheumatol Int
Prif Awduron: Kastritis, Efstathios, Kitas, George D., Vassilopoulos, Dimitrios, Giannopoulos, Georgios, Dimopoulos, Meletios A., Sfikakis, Petros P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer Berlin Heidelberg 2020
Pynciau:
Review
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7353833/
https://ncbi.nlm.nih.gov/pubmed/32654078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00296-020-04629-x
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg